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Abstraet - -A monoclonal antibody has been obtained that recognizes an 
antigen encoded by human chromosome 11. We present evidence that this 
monoclonal antibody recognizes the same or a similar antigenic activity as 
that previously called al. Genetic information necessary for at expression 
and recognition by the monoclonal antibody both map to 1 lpl  3 --~ 1 lpter. 
Mutants that have lost at are no longer recognized by the monoclonal 
antibody. The macroglycolipid fraction of human erythrocyte membranes 
which contains the al antigenic activity is able to convert antigen-negative 
Chinese hamster ovary cells into cells which are killed by the monoclonal 
antibody plus complement. 
INTRODUCTION 
Previous work from this and other laboratories has identified several 
different human cell-surface antigens coded for by human chromosome 11 
using human-rodent somatic cell hybrids (1-7). These antigens have been 
identified utilizing species-specific antisera. The ability to prepare monoclonal 
antibodies to these antigens makes more precise analysis possible. 
In this paper, we describe an IgM monoclonal antibody that recognizes 
an antigen coded for by chromosome 11. This antigen maps on l lp13 
1 l pter and, using mutant and glycolipid conversion analyses, we show that 
this monoclonal recognizes the antigen activity we previously designated al 
(also referred to as SA11-1 and S1). 
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MATERIALS AND METHODS 
Cell Lines and Cell Culture. The following cell lines were used: CHO- 
K1, a Chinese hamster ovary cell line; J1, a human-Chinese hamster ovary 
hybrid which contains human chromosome 11 as its only human chromosome 
(8); J l  7, 11,23, 35 (9, 10), subclones of J1; a panel of independently isolated 
human-Chinese hamster hybrids containing different combinations of human 
chromosomes; and HeLa and a variant HeLa line. These cells were cultivated 
in F12FC5 (1!) .  
For hybridoma production the human cell lines UM-SCC-1, a squamous 
cell carcinoma line established at the University of Michigan (12), SK- 
MEL-28, a malignant melanoma line (13), WI-38, a normal human fibroblast 
line, and SK-OV-3, an ovarian adenocarcinoma line, were used. SK-MEL-28, 
WI-38, and SK-OV-3 were all obtained from the tumor cell bank at the 
Sloan-Kettering Institute. Human cell lines were maintained in Eagle's 
minimum essential media (MEM) supplemented with 2 mM glutamine, 1% 
nonessential amino acids, 100 IU/ml  penicillin, 100 ~tg/ml streptomycin, and 
15% fetal bovine serum. NS-1 mouse myeloma cells (14) were obtained from 
B. Grossman and were cultured in RPMI 1640 medium. 
Hybridoma Isolation and Monoclonal Antibody Production. BALB/c 
mice were immunized intraperitoneally with 30 million viable cells of the 
human squamous cell carcinoma line UM-SCC-t .  At 8 and 30 weeks after 
immunization, the mice were given booster inoculations of 3 million cells. 
Three days after the last immunization, 108 immune spleen cells were fused to 
107 NS- 1 myeloma cells (14) with 30% polyethylene glycol 1000 (Koch-Light 
Laboratories, Ltd., Berks., England). Fused cells were plated in petri dishes in 
complete Iscove's medium containing 20% FCS, 36 mM NaHCO3, and 50 
#g/ml garamycin. After a 48-hr incubation at 37 ~ cells were plated in 96-well 
plates (Corning 25860) in complete Iscove's medium (Gibco Cat. No. 
430-2200, Grand Island, New York) containing 1 x 10 -4 M hypoxanthine, 
1.6 • 10 -5 M thymidine, and 4 x 10 -7 M aminopterin (HAT) (15). The 
medium in each well was changed twice before testing for antibody produc- 
tion. Supernatant from wells containing hybrids was assayed for specific 
antibody by a mixed hemadsorption assay (13) against UM-SCC-1 cells. 
Positive supernatants were then tested against a panel of human cell lines 
including UM-SCC-1, a fibroblast line, a melanoma, and an ovarian carci- 
noma. Hybridomas giving unique patterns of reactivity were selected, sub- 
cloned, and the resulting monoclonal antibody-containing supernatants were 
tested extensively for reactivity to human malignant and normal cell lines of 
different histologic types. Established hybridoma cultures were maintained in 
Iscove's medium. Monoclonal antibody E7 is an IgM antibody that binds to 
nearly all human cells. 
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Fig. 1. Percentage survival in E7 monoclonal antibody and complement of CHO-K1 o and J 1 o. 
In contrast to the CHO-K1 parental cell, J1 was readily killed. The percentage survival is relative 
to a complement control. 
Antigen Assay. Cells were plated in the presence of complement (1.5% 
normal rabbit serum) in increasing concentrations of antiserum or hybridoma 
supernatant; 6 days later, the plates were fixed and stained, the number of 
colonies determined, and survival curves plotted. The difference between cells 
scored as killed or not killed is illustrated in Fig. 1. 
Karyotypic and Isozyme Analysis of Hybrids. Human chromosome 
content of hybrids was determined cytogenetically by trypsin banding and 
Giemsa-ll staining (8, 16) and by analyzing isozymes specific for each 
human chromosome as previously described (17). 
Glycolipid Conversion. The macroglycolipid (MGL) fraction of human 
red blood cell membranes was prepared by the method of Dejter-Juszynski et 
al. (10, 18). CHO-K1 cells were incubated with a solution of MGL (1 mg/ml) 
in PBS for 30 min. Cells were then washed and tested with monoclonal 
antibody using the standard cytotoxicity assay. Control cells were incubated 
for 30 min in PBS. 
RESULTS 
Chromosomal Assignment. Survival curves showing the behavior of J1, a 
human-Chinese hamster hybrid containing chromosome 11 as its only human 
chromosome (8), and CHO-KI, the Chinese hamster parental cell line, when 
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Table 1. Segregation Analysis of Antigen Recognized by E7 Monoclonal Antibody 
Killing action 
Human chromosome displayed by E7 
Hybrid present monoclonal antibody 
822-19B 1,2,3,5,6,10,1 I, 14,15,19,20,21,22 Killed 
7 5 0 - 7  4,9,11,16,X Killed 
6 8 - 1 1  1,5,6,8,9,11,12,14,15,19,20,21,22,X Killed 
68-14 4,5,6,7,8,9,11,12,14,15,18,19,20,21,22 Killed 
7 2 - 4 B  3,8,10,11,12,17,21 Killed 
822-5a 2,9,11,12,13,19,21,22 Killed 
68-12 2,3,4,5,6,7,9,l 1,12,15,16,18,19,20,21,22 Killed 
822-59b 4,7,14 Not killed 
68-10A 4,8,12,14,15,18,19,21,22,X Not killed 
68-16 5,6,8,21,22 Not killed 
tested with the E7 monoclonal  an t ibody  are  shown in Fig. 1. N o  complement-  
media ted  cytotoxici ty  is demons t rab le  for C H O - K 1  at  concentrat ions  of 
monoclonal  an t ibody 1000 t imes grea ter  than tha t  which is complete ly  lethal  
to J1. This  provides evidence tha t  this ant igen act ivi ty is dependent  on the 
presence of  human  chromosome 11. To confirm this, a panel  of  independent ly  
isolated h u m a n - C h i n e s e  hams te r  hybrids  which contain a combinat ion  of 
human  chromosomes was tested with E7 monoclonal  ant ibody.  As shown in 
Table  1, there  was 100% concordance  of  this act ivi ty  with the presence of  
chromosome 11. 
Regional Mapping. W e  have previously isolated and charac te r ized  a 
regional  clone panel  from J 1 containing different  delet ions of  chromosome 11 
(9, 19). Member s  of this panel  were tested with E7, and the results a re  shown 
in Table  2, which indicate  the  genet ic  component  responsible for E7 act ivi ty  
resides on the short  a rm of  11 (1 lp13 ~ 1 lp t e r ) .  
Mutant Analysis. Because we have previously identif ied human  ant igens 
a~ and a3 with the  same map  location (9), we examined a mutan t  which was 
a l -  a3 + and contained a normal -appear ing  chromosome 11 (10). This  mu- 
Table 2. Characteristics of Hybrids and Human Cells Tested with E7 Monoclonal Antibody 
Killing action displayed by 
Deletions in Antigenic survival curve analysis to E7 
Cell chromosome 11 phenotype monoclonal antibody 
J1 None a~+a2+a3 + Killed 
J1-7 pl 1 ~ pter a~-a2+a3 - Not killed 
Jl-11 q13 ~ qter a~+a2 a3 + Killed 
J1-23 pl 3 --~ pter al-a2+a3 - Not killed 
J 1-35 None al-az+a3 + Not killed 
HeLa al +az+a3 + Killed 
Altered HeLa a~-a2+a3 + Not killed 
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tant clone showed no cytotoxicity when tested with the monoclonal antibody 
(Table 2). This suggests that E7 may recognize the a~ antigen but not a 3. 
We have previously isolated and described a variant clone of HeLa which 
differs in morphology from the standard S3-HeLa (20). The altered HeLa has 
a round morphology and attaches poorly to plastic. Figure 2 compares the 
morphology of the altered HeLa with that of standard HeLa. We have 
previously shown that altered HeLa does not express the a~ antigen by its 
failure to adsorb am activity from a~ + polyclonal antisera. It is also unable to 
elicit anti-a~ antibodies in rabbits in contrast to standard HeLa. Altered HeLa 
does express a2 and a3, two other chromosome 11 antigen-associated activities. 
The monoclonal E7 was, therefore, tested with these two HeLa cell lines, and 
it was found that standard HeLa was killed and altered HeLa was not (Table 
2). Mutant analysis, therefore, shows that al and the antigen recognized by E7 
map on the same region of chromosome 11 and variants of both J1 and HeLa 
which have lost the a~ antigen have lost the antigen recognized by E7. 
Glycolipid Conversion. We have previously shown that al antigenic 
activity is found in the macroglycolipid (MGL) fraction of the human 
erythrocyte membranes (10). Other workers have shown that it is possible to 
convert cholera toxin-resistant cells to cholera toxin sensitivity using the 
glycolipid GM1 ganglioside (21, 22). Lymphocytes have been made reactive to 
a teratoma-specific antiserum by treating them with organic extracts of 
teratoma cells (23). We therefore tested the ability of the MGL fraction to 
convert CHO-K1 cells to antigen positive. As was shown previously (Fig. 1), 
CHO-K1 cells are not killed by E7 at high concentrations but, as shown in Fig. 
3, MGL treatment produced cells which were killed by the monoclonal 
antibody. This provides evidence that the MGL fraction which contained al 
activity also has activity for E7. We therefore conclude that E7 recognized the 
same or a similar antigenic activity as that previously identified as av 
DISCUSSION 
The availability of the E7 monoclonal antibody which recognizes the a~ 
cell-surface antigenic determinant will allow further elucidation of the 
structure of this molecule. Monoclonal antibodies which are specific for single 
antigenic determinants will be particularly useful when studying complex 
structures like macroglycolipids. The E7 monoclonal antibody belongs to the 
IgM class and is extremely efficient in complement-mediated cytotoxicity 
tests, which makes it useful for the types of genetic analyses we use to study 
cell-surface molecules. It will also be useful for establishing the cellular and 
tissue distribution of this antigen. To date, the only human cell line identified 
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Fig. 3. Percentage survival in E7 monoclonal antibody and complement of control CHO-K1 [] 
and CHO-K1 cells converted with the macroglycolipid fraction (MGL) of human red blood cell 
membranes o. Treatment  of CHO-K1 with M GL  converted this cell from one which was resistant 
to the action of E7 to one that was readily killed. 
being tested and lines with significant quantitative differences have been 
identified. 
A number of cell-surface molecules have been assigned to human 
chromosome 11. The relationship of these antigens to the antigens we have 
called al, a2, and a3 is not firmly established. Indeed we have genetic evidence 
that the activity we call a2, which is encoded for by the long arm of 11, consists 
of at least three separate activities. Barnstable et al. (5) have described 
monoclonal antibody which recognizes an antigen encoded for by the short 
arm of 11 which appears to be a glycolipid. This monoclonal antibody, W6-34, 
also appears to recognize the antigen we call a] (24). This was determined 
using a similar experimental approach to that described for characterization 
of the E7 monoclonal antibody. We have also shown that the 105,000-dalton 
glycoprotein which is recognized by monoclonal antibody F10.44.2, assigned 
to chromosome 11 by Goodfellow et al. (6), maps on the same region of 
chromosome 11 as the a 3 antigen (24). Messer Peters et al. (7) have recently 
assigned an 85,000-dalton glycoprotein to chromosome 11 using a monoclonal 
antibody 4F2, which appears different from those previously described. 
The availability of these different monoclonal antibodies recognizing 
cell-surface antigens encoded for by human chromosome 11 should facilitate 
further manipulation and study of this human chromosome. 
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